Articles tagged with Cancer Medication
A study led by Massachusetts General Hospital found that early treatment with lorlatinib improved survival rates and reduced the risk of brain metastasis in ALK-positive lung cancer patients. Lorlatinib was shown to be effective as a first-line therapy, reducing the risk of cancer progression or death by 72%.
Researchers designed DNA-based nanogels that break down and release chemotherapeutic contents only in cancer cells. The nanogels use biomarkers like FEN1 to differentiate between healthy and cancerous cells, reducing the impact on normal cells.
Researchers have discovered that Netrin-G1 helps pancreatic cancer cells survive by protecting them from the immune system and supplying them with nutrients. The study found that an antibody targeting Netrin-G1 was able to stunt tumor development in mice, demonstrating its potential as a new treatment.
A team of scientists at Tokyo University of Science has developed a novel synthesis method to create phenazinones, which show high cytotoxicity towards cancer cells. This breakthrough could lead to the creation of new anticancer drugs with minimal side effects.
The EA2176 study aims to enroll 205 patients in the US with inoperable advanced squamous cell anal cancer, comparing standard chemotherapy with or without nivolumab. The trial seeks to determine if adding immunotherapy will prolong progression-free survival and reduce symptoms.
A promising MS drug called TEPP-46 has shown worsening effects on the disease in mouse models, causing inflammation redirection and T cell changes. The research suggests caution before moving the drug to human trials.
Researchers have identified RNF43 as a potential biomarker to predict which cancers will respond to Wnt inhibitor therapies. This discovery brings personalized medicine in cancer therapy closer to reality, offering new hope for targeted treatment and improved patient outcomes.
A SWOG Cancer Research Network study found that the ipilimumab and nivolumab combination shrinks rare angiosarcoma tumors in 25% of patients, with a 60% response rate for those with facial or scalp lesions, offering new hope for treatment
A clinical trial is planned to evaluate personalized drug screens for medulloblastoma, a deadly form of pediatric brain cancer. The approach uses tumor cells from biopsies and has been shown to identify effective therapies that cannot be predicted using other methods.
Researchers found a significant rise in early-stage cancer diagnoses following ACA's Medicaid expansion, while late-stage cancer rates decreased over time. The study suggests that increased access to healthcare led to better cancer screening and treatment outcomes.
A new study from Penn Medicine researchers found that early and repeated exposures to diagnostic imaging, such as X-rays and CT scans, may increase the risk of testicular cancer. The study suggests that reduced medically unnecessary testicular exposure could be considered to reduce radiation dose and optimize shielding practices.
A researcher at Indiana University School of Medicine has received a $2.9 million grant to develop a drug that could make radiation therapy more effective in treating lung cancer and other solid tumors.
A synthetic protein nanoparticle has been developed that can deliver cancer-killing drugs directly to malignant brain tumors. In a study, the treatment led to long-term survival in seven out of eight mice with glioblastoma, with no signs of regrowing tumor cells.
Research at Humane Society International found that human organoid models outperform xenografts in predicting patient responses and developing new medicines. Funding for human biology-based approaches remains scarce, highlighting a need to accelerate the transition to more effective non-animal technologies.
A new predictive model estimates personal risk for advanced polyps and colon cancer in average risk individuals, helping physicians determine screening options. The study identifies lower and higher risk groups among average risk individuals, with approximately 10% deemed high risk for a colonoscopy.
The VA Integration Support Program provides $50,000 grants to VA medical centers to facilitate veteran enrollment in SWOG and NCTN trials. This initiative aims to increase access to targeted treatments and immunotherapies for veterans with cancer.
A new study shows that the introduction of new cancer drugs between 2000 and 2016 led to a significant reduction in mortality rates for patients with 15 common types of cancer, including breast, lung, and colorectal cancer. The study estimates that these drug approvals saved over 1.2 million lives during this period.
A Boston University School of Medicine study reveals a widening gap between high deductible health plan (HDHP) enrollment and the availability of health savings accounts (HSAs), exacerbating health inequities among Black, Hispanic, and lower-income populations.
Researchers found that a commonly prescribed anti-depressant can halt the growth of childhood sarcoma by targeting a specific receptor, offering hope for novel treatment strategies. The study provides a new paradigm for controlling tumour-driving receptors and could lead to the development of specific therapeutics.
Researchers discovered that clonal hematopoiesis, a phenomenon where non-cancer DNA mutations are present in blood plasma, is confounding prostate cancer liquid biopsy results. This can lead to false positives and incorrect treatment for patients undergoing liquid biopsies.
Researchers have developed a novel antibody-drug conjugate that selectively recognizes and penetrates pancreatic tumors, reducing tumor size and metastasis. The treatment, which uses MRI-based molecular imaging to monitor its effect, shows promise as a more precise approach than existing treatments.
The study generated a valuable resource to aid in predicting drug sensitivity, understanding therapeutic resistance mechanisms, and identifying optimal combination treatment strategies. The dataset includes expression changes in over 200 clinically relevant proteins across more than 300 cell lines after treatment with 168 different com...
Researchers have identified a new class of sedatives that could enhance the effectiveness of radiation and immunotherapy treatments for metastatic melanoma, reducing toxic side effects. In animal models, these treatments resulted in improved infiltration of immune cells into tumors, shrinking or eliminating cancerous growths.
Researchers found beta-blocker Propranolol reduces the spread of cancer in lungs with an inflammatory profile similar to COVID-19. Clinical trials are proposed to explore its effectiveness against COVID-19.
Researchers have developed a new treatment that induces an integrated immune response in tumors of patients with pancreatic and colorectal cancers, which are resistant to immunotherapy. The treatment, plerixafor, works by interrupting an immunosuppressive pathway, allowing critical immune cells to infiltrate the tumors.
Researchers at Massachusetts General Hospital have identified four distinct physical properties of cancer, including elevated solid stress and increased stiffness, which contribute to its sustained growth and destructive power. These findings point to new research opportunities and treatment approaches.
HSE Faculty of Chemistry scientists discovered a new anti-cancer molecule, diphenylisoxazole, which is easily synthesized using available compounds. The molecule inhibits tubulin polymerization and shows effectiveness on both sea urchin embryos and human cancer cells.
Researchers at ChristianaCare's Helen F. Graham Cancer Center & Research Institute have identified a link between two crucial signaling pathways in the development and growth of colon cancer. The study found that an imbalance between WNT and RA signaling can lead to the evolution of colorectal cancer from stem cell populations.
A team led by Dr. Katherine L. Nathanson has been awarded $5.4 million to continue researching the genetic risk factors of testicular cancer, which affects men aged 15-45 in the US and Europe. The study aims to identify novel susceptibility genes and provide data for surveillance of high-risk individuals.
Researchers at the University of Virginia have discovered that cancer alters the three-dimensional structure of chromosomes to create a comfortable home for itself inside cells. This remodeling is linked to changes in gene expression and can be targeted with specific drugs, offering new approaches to cancer treatment.
The study demonstrated a paradigm shift in treating AML, proving that genetic information matching leads to better survival rates than traditional one-size-fits-all treatment. Patients who opted for precision medicine experienced lower early death rates and superior overall survival compared to those receiving standard of care.
A new 'next generation' BRAF inhibitor, PLX8394, has shown promising results in an early patient trial for treating various types of cancer. The treatment, taken with cobicistat, resulted in a partial response in 22% of patients, including those with glioma and bowel cancer.
The KRYSTAL-1 phase I/II clinical trial has shown that adagrasib can shrink tumours and is well-tolerated by patients with non-small cell lung cancer, colorectal cancer, and other solid tumours. The KRAS G12C mutation affects approximately 14% of lung adenocarcinomas and 4% of colorectal cancers.
Researchers found that high concentrations of sunitinib in tumors, but not blood plasma, are associated with improved patient outcomes. The study's results suggest a safer and more effective treatment strategy for patients with advanced cancers.
The ESMO Asia Virtual Congress 2020 examined the efficacy of new therapies for prevalent cancer types in the Asia-Pacific region. The scientific program featured key research areas, including neo-adjuvant immuno-oncology and molecular stratification.
Renowned scientist Sir Peter Ratcliffe emphasizes the importance of passion-driven research in science, contrasting it with the expectation to solely focus on COVID-19. He draws from his own research on hypoxia and its role in various human diseases, highlighting the potential of this field for drug discovery and treatment.
Researchers at the University of Alberta have identified a new precision cancer drug for blood cancers that targets enzymes modifying proteins for cell signalling. The treatment, PCLX-001, has shown promising results in killing various types of cancer cells while leaving non-cancerous cells unharmed.
Researchers created an experimental AI platform called DrugCell that matches tumors to the best drug combinations. The system was trained on over 500,000 cell line/drug pairings and validated in laboratory experiments, showing promise for precision cancer therapy.
Research reveals thymoquinone's ability to induce apoptosis and DNA damage in 5-Fluorouracil-resistant colorectal cancer, demonstrating its potential as a therapeutic agent. The compound targets CSCs enriched from both sensitive and resistant cell lines, suggesting a promising effect on chemoresistant cells.
Researchers found that angiotensin receptor blockers (ARBs), commonly used for high blood pressure and heart failure, may increase the likelihood of responding to anti-PD(L)1 therapy. Patients taking ARBs showed a statistically significant improvement in objective response rate and complete response rate compared to those not taking them.
A genome-wide association study found two genetic variants associated with high blood pressure and kidney toxicity in cancer patients treated with bevacizumab. The variants, rs6770663 and rs339947, can be used to predict which patients are at risk of severe side effects.
Researchers have identified silent ancient DNA elements in our genome that, when reactivated, stimulate the immune system to fight cancer. The discovery of ADAR1, an enzyme used by cancer cells to evade detection, opens up a new field of cancer therapies.
Researchers developed a new method to test potential cancer drugs in mice, allowing them to evaluate multiple genetic variants of the same cancer. This approach could accelerate the development of better treatments by increasing the number of tumour models tested with fewer animals.
Three new trans-Atlantic research teams will tackle neuroblastomas, Ewing sarcoma and other difficult-to-treat cancers in children. They aim to develop precision radiotherapy, re-engineer T-cells for immunotherapies and target cancer-causing gene mutations.
Researchers found that combining Th1 cytokines IFN-gamma and TNF-alpha with the small molecule Akt antagonist MK-2206 maximizes indicators of apoptotic cell death in breast cancer cells. The study also suggests a combined therapy approach for Akt-targeting drugs that incorporates recombinant Interferon-gamma.
A Penn-developed machine learning tool helps sustain end-of-life care discussions with cancer patients, tripling the rate of those discussions. The study shows that clinicians engage more in conversations when prompted by an algorithm and a behavioral nudge.
International scientists challenge their colleagues to make Artificial Intelligence (AI) research more transparent and reproducible to accelerate the impact of their findings for cancer patients. The authors offer numerous frameworks and platforms that allow safe and effective sharing of data, computer code, and predictive models.
Researchers at the University of California, Irvine discovered that skin cells communicate with each other through protein signals to stop growing and prevent cancer. This finding could lead to new treatment options and potentially prevent melanomas from developing in the first place.
Research shows that intensive smoking cessation counseling for newly diagnosed cancer patients improves quality of life, reduces complications and increases survival. The study found that providing six months of inexpensive tobacco cessation support at diagnosis can result in significant cost savings and improved health outcomes.
The Tumor Neoantigen Selection Alliance (TESLA) has discovered five characteristics that strongly indicated which cancer markers were most likely to generate an immune response. The data model accurately predicted 75% of effective neoantigen targets and filtered out 98% of ineffective ones.
Researchers have discovered a combination of MEK and SHP2 inhibitors effective in targeting the mechanism driving cancer growth in malignant peripheral nerve sheath tumours. The treatment has shown promise in both cell culture and mouse models, offering hope for improved treatment outcomes for patients.
A pay-for-performance program increased prescriptions of high-quality, evidence-based cancer drugs by 5.1 percentage points without significantly changing total spending on care. The program improved the rate of high-value prescribing in oncology, leading to better patient outcomes and longer life expectancy.
Scientists have developed a technique that quickly identifies optimal synergistic combinations of anticancer drugs, reducing tumour growth by 80% and outperforming chemotherapy. The technology, called TGMO, achieves results in under two weeks, paving the way for personalized, effective, and safe cancer treatment.
Researchers found that 91% of patients with limited stage DLBCL who received no radiation were alive five years after treatment. A PET scan after three cycles of R-CHOP can determine if patients need additional chemotherapy or radiation. This approach may improve patient outcomes and reduce toxicity.
Researchers have developed a new hyperpolarisation technique to monitor cancer drug efficacy, potentially replacing tissue biopsies. The method detects biomarkers like FOXM1, indicating drug resistance in ER-positive breast cancer.
Researchers at Lund University identified and tested a drug effective against neuroblastoma, showing promising results with tumor growth prevention and prolonged survival in mice. The KSP inhibitor has been shown to be especially effective against the aggressive variant, which often has poor prognosis.
Preliminary results from two large clinical trials investigating a new PD-1-based immune therapy for metastatic cervical cancer suggest improved response rates and potential new treatment options. The trials involved over 150 patients with recurrent or metastatic cervical cancer and tested the combination of balstilimab and zalifrelimab.
Researchers at ETH Zurich have developed a non-invasive method for concentrating and releasing drugs in the brain with pinpoint accuracy using focused ultrasound. The new technique aggregates drugs at specific sites, reducing dosage requirements by 1,300 times, and preserves physiological barriers between blood and nervous tissue.
The Zero Childhood Cancer Personalised Medicine Program has identified the molecular basis of childhood cancers in over 90% of cases and found at least one new potential treatment option in 70% of children. Early results show that tumours shrank or stopped growing in 30% and 40% of cases, respectively.
Researchers developed a new nanoscale metal-organic framework design to deliver targeted, personalized vaccines for cancer treatment. The approach leverages radiation treatment and the adaptive immune response to kill cancer cells directly and trigger an immune response against tumor cells.